

AUROBINDO PHARMA LIMITED

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

PART I STATEMENT OF STAND ALONE/CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED 31.03.2013

Particulars	Stand alone				Consolidated					
	Three months ended			Year Ended	Three months ended			Year Ended		
	31.03.2013	31.12.2012	31.03.2012		31.03.2013	31.12.2012	31.03.2012		31.03.2013	
1 Income from operations										
(a) Net sales/ income from operations (Net of excise duty)	145,524	141,263	107,214	535,291	420,461	155,268	155,195	117,075	578,312	455,056
(b) Other operating income	1,769	1,874	1,997	7,219	7,684	1,769	1,814	1,997	7,219	7,684
Total income from operations (net)	147,293	143,137	109,211	542,510	428,145	157,037	157,009	119,072	585,531	462,740
2 Expenses										
(a) Cost of material consumed	73,222	85,423	64,320	305,364	239,329	75,580	84,470	66,451	309,144	242,436
(b) Purchase of stock-in-trade	1,671	2,229	1,960	7,809	3,552	5,502	3,010	4,505	16,958	10,144
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	5,397	(8,873)	490	(12,108)	8,987	(615)	(9,260)	(6,797)	(27,025)	(605)
(d) Employee benefits expense	11,127	10,995	9,126	43,142	36,410	17,518	16,682	13,908	66,331	53,568
(e) Depreciation and amortisation expense	4,598	4,224	3,838	17,139	14,294	6,928	6,079	5,392	24,874	20,053
(f) Provision for decline in the value of long-term investment	5,100	-	2,687	6,900	2,687	-	-	-	-	-
(g) Other expenses	25,479	25,113	20,263	95,597	77,681	35,044	36,198	26,965	131,216	96,183
Total expenses	126,594	119,111	102,684	463,843	382,940	139,957	137,179	110,424	521,498	421,779
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	20,700	24,026	6,527	78,667	45,205	17,080	19,830	8,648	64,033	40,961
4 Other Income	663	108	830	1,501	1,906	1,409	564	592	2,854	2,470
5 Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)	21,363	24,134	7,357	80,168	47,111	18,489	20,394	9,240	66,887	43,431
6 Finance costs (refer note 7)	2,595	2,850	3,250	11,474	9,311	3,160	3,312	3,522	13,133	10,278
7 Foreign exchange (Gain)/Loss (refer note 7)	(954)	6,496	(9,612)	12,382	19,596	130	7,336	(10,345)	16,344	22,330
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	19,722	14,788	13,719	56,312	18,204	15,199	9,746	16,063	37,410	10,823
9 Exceptional item	-	-	-	-	31,986	-	-	132	-	32,118
10 Profit/(Loss) from ordinary activities before tax (8-9)	19,722	14,788	13,719	56,312	(13,782)	15,199	9,746	15,931	37,410	(21,295)
11 Tax expense/(credit)	3,368	360	4,928	6,713	(9,521)	4,452	646	5,189	8,271	(8,811)
12 Net Profit/(Loss) for the period (10-11)	16,354	14,428	8,791	49,599	(4,261)	10,747	9,100	10,742	29,139	(12,414)
13 Minority Interest	-	-	-	-	-	(114)	(81)	(58)	(246)	(64)
14 Net Profit/(Loss) after taxes and minority interest (12-13)	16,354	14,428	8,791	49,599	(4,261)	10,861	9,181	10,800	29,385	(12,350)
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	2,912	2,911	2,911	2,912	2,911	3,73	3,15	3,71	10,09	(4,24)
16 Reserves excluding Revaluation Reserve	290,998	246,406	17,04	17,04	(1,46)	3,73	3,15	3,71	10,09	(4,24)
17 Earnings per share of Rs.1/- each (not annualised)										
(a) Basic	5.62	4.96	3.02	17.04	(1.46)	3.73	3.15	3.71	10.09	(4.24)
(a) Diluted	5.61	4.96	3.02	17.02	(1.46)	3.73	3.15	3.71	10.09	(4.24)



NOTES:

- 1 The audited financial results as reviewed by the Audit Committee have been approved by the Board at its meeting held on May 30, 2013.
- 2 The consolidated audited financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Ventures.
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 FOB value of exports for standalone is Rs. 389,353 lakhs for the current year (March 31, 2012: Rs. 292,108 lakhs).
- 5 Net sales for the current year include dossier income in standalone of Rs. 2,976 lakhs (March 31, 2012: Rs. 4,964 lakhs) and in consolidated of Rs. 7,598 lakhs (March 31, 2012: Rs. 5,985 lakhs).
- 6 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs. Nil, Rs. 4,999 lakhs, Rs. 4,789 lakhs for three months ended March 31, 2013, Dec 31, 2012, and Mar 31, 2012 respectively and Rs. 13,532 lakhs for the year ended March 31, 2013 and 17,447 lakhs for the year ended March 31, 2012 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of 'AS 16' on Borrowing costs.
- 7 The Company incorporated a new wholly owned subsidiary viz. Curepro Parenterals Limited on April 19, 2013. Euglia Pharma Specialities Limited has become wholly owned subsidiary of the Company w.e.f. May 2, 2013.
- 8 The Board recommended final dividend @50% on the equity share capital of the Company i.e. Re. 0.50/- per share subject to approval of members. This is in addition to interim dividend @100% on equity share capital of the Company i.e. Re. 1/- per share paid in February, 2013.
- 9 The figures of last quarter are the balancing figures between audited figures in respect of the full financial year ended March 31st and unaudited published year to date figures upto the third quarter ended December 31st. The unaudited consolidated results published year to date figures upto the third quarter ended December 31st were not subject to limited review and the unaudited standalone results were subject to limited review.
- 10 Exceptional item in the standalone and consolidated financial results for the year ended March 31, 2012 pertains to the redemption premium (Yield to Maturity) on redemption of Foreign currency convertible bonds
- 11 Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current year presentation.



Place: Hyderabad
Date: May 30, 2013

www.aurobindo.com

N. Govindarajan
Managing Director

By Order of the Board

Statement of Assets and Liabilities

Rs. In lakhs

Particulars	Stand alone		Consolidated	
	As At 31.03.2013 Audited	As At 31.03.2012 Audited	As At 31.03.2013 Audited	As At 31.03.2012 Audited
A				
EQUITY AND LIABILITIES				
1 Shareholders' funds				
(a) Share capital	2,912	2,911	2,912	2,911
(b) Reserves and surplus	290,998	246,406	257,665	231,054
Sub-total - Shareholders' funds	293,910	249,317	280,577	233,965
2 Share application money pending allotment	-	-	-	-
3 Minority interest			1,100	1,021
4 Non-current liabilities				
(a) Long-term borrowings	104,106	83,374	114,826	96,463
(b) Deferred tax liabilities (net)	6,794	379	6,800	384
(c) Long-term provisions	850	412	900	424
Sub-total - Non-current liabilities	111,750	84,165	122,526	97,272
5 Current liabilities				
(a) Short-term borrowings	173,390	160,821	223,612	160,821
(b) Trade payables	90,128	58,486	96,874	66,014
(c) Other current liabilities	6,804	40,577	15,087	58,034
(d) Short-term provisions	6,475	5,755	8,009	6,636
Sub-total - Current liabilities	276,797	265,639	343,582	291,505
TOTAL - EQUITY AND LIABILITIES	682,457	599,121	727,785	623,762
B				
ASSETS				
1 Non-current assets				
(a) Fixed assets	217,824	218,483	280,195	278,592
(b) Goodwill on consolidation	-	-	5,544	5,414
(c) Non-current investments	70,794	61,032	2,224	1,986
(d) Deferred tax assets (net)	-	-	-	543
(e) Long-term loans and advances	28,910	17,849	24,281	10,812
(f) Other non-current assets	1,858	12	1,866	12
Sub-total - Non-current assets	319,386	297,376	314,110	297,359
2 Current assets				
(a) Current investments	4	1,867	4	1,867
(b) Inventories	143,173	121,926	192,359	154,556
(c) Trade receivables	173,059	142,628	158,698	123,996
(d) Cash and cash equivalents	11,458	1,401	20,845	7,086
(e) Short-term loans and advances	27,598	26,248	33,208	31,485
(f) Other current assets	7,779	7,675	7,561	7,413
Sub-total - Current assets	363,071	301,745	413,675	326,403
TOTAL - ASSETS	682,457	599,121	727,785	623,762

